Current and future molecular diagnostics in non-small-cell lung cancer

被引：13

作者：

Li, Chun Man ^{[1
]}

Chu, Wing Ying ^{[1
]}

Wong, Di Lun ^{[1
]}

Tsang, Hin Fung ^{[1
]}

Tsui, Nancy Bo Yin ^{[1
]}

Chan, Charles Ming Lok ^{[2
,3
]}

Xue, Vivian Wei Wen ^{[1
]}

Siu, Parco Ming Fai ^{[1
]}

Yung, Benjamin Yat Ming ^{[1
]}

Chan, Lawrence Wing Chi ^{[1
]}

Wong, Sze Chuen Cesar ^{[1
]}

机构：

[1] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Fac Hlth & Social Sci, Hong Kong, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Sir YK Pao Ctr Canc,Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China

[3] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2015年 / 15卷 / 08期

关键词：

ALK rearrangement; EGFR mutation; molecular diagnostics; non-small-cell lung cancer; TYROSINE KINASE INHIBITORS; TRANSBRONCHIAL NEEDLE ASPIRATION; FACTOR-RECEPTOR MUTATIONS; COPY NUMBER ABERRATIONS; RANDOMIZED PHASE-II; EGFR MUTATION; ROS1; REARRANGEMENTS; KRAS MUTATIONS; DIGITAL PCR; ACTIVATING MUTATIONS;

D O I：

10.1586/14737159.2015.1063420

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The molecular investigation of lung cancer has opened up an advanced area for the diagnosis and therapeutic management of lung cancer patients. Gene alterations in cancer initiation and progression provide not only information on molecular changes in lung cancer but also opportunities in advanced therapeutic regime by personalized targeted therapy. EGFR mutations and ALK rearrangement are important predictive biomarkers for the efficiency of tyrosine kinase inhibitor treatment in lung cancer patients. Moreover, epigenetic aberration and microRNA dysregulation are recent advances in the early detection and monitoring of lung cancer. Although a wide range of molecular tests are available, standardization and validation of assay protocols are essential for the quality of the test outcome. In this review, current and new advancements of molecular biomarkers for non-small-cell lung cancer will be discussed. Recommendations on future development of molecular diagnostic services will also be explored.

引用

页码：1061 / 1074

页数：14

共 154 条

[1]

Abdulkareem Imran Haruna, 2013, Niger Med J, V54, P79, DOI 10.4103/0300-1652.110033

[2] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics [J].

Akinleye, Akintunde ;

Avvaru, Parthu ;

Furqan, Muhammad ;

Song, Yongping ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[3] Cancer stem cells in lung cancer: Evidence and controversies [J].

Alamgeer, Muhammad ;

Peacock, Craig D. ;

Matsui, William ;

Ganju, Vinod ;

Watkins, D. Neil .

RESPIROLOGY, 2013, 18 (05) :757-764

[4] Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma [J].

Allo, Ghassan ;

Bandarchi, Bizhan ;

Yanagawa, Naoki ;

Wang, Ami ;

Shih, Warren ;

Xu, Jing ;

Dalby, Morgan ;

Nitta, Hiroaki ;

To, Christine ;

Liu, Ni ;

Sykes, Jenna ;

Tsao, Ming S. .

HISTOPATHOLOGY, 2014, 64 (06) :826-839

[5] The Dual ALK/EGFR Inhibitor AP26113 Also Potently Inhibits Activated and Gatekeeper Mutant Forms of ROS1 [J].

Anjum, R. ;

Zhang, S. ;

Squillace, R. ;

Clackson, T. ;

Garner, A. P. ;

Rivera, V. M. .

EUROPEAN JOURNAL OF CANCER, 2012, 48 :50-50

[6]

[Anonymous], PROD PAG THER EGFR P

[7]

[Anonymous], ANN ONCOL

[8]

[Anonymous], WORLDW DAT

[9]

[Anonymous], NEW EM HLTH TECHN LU

[10]

[Anonymous], PROD PAG THER KRAS P

← 1 2 3 4 5 6 7 8 9 10 →